Pricing Log in Create free account

Jazz Pharmaceuticals PLC (JAZZ) vs Summit Therapeutics PLC (SMMT)

Jazz Pharmaceuticals PLC and Summit Therapeutics PLC are both Biotechnology companies. Jazz Pharmaceuticals PLC is the larger, with a market value of $14.6B against $11.3B — 1.3× the size. Summit Therapeutics PLC has negative trailing earnings, so its P/E is not meaningful; Jazz Pharmaceuticals PLC trades at 62.6×. Jazz Pharmaceuticals PLC grew revenue faster over the last twelve months: 13.5% against −61.0%. Jazz Pharmaceuticals PLC has the higher net margin (4.37% vs 0.00%) and the higher return on invested capital (3.86% vs 0.00%). Across the 18 metrics below, Jazz Pharmaceuticals PLC leads on 14 and Summit Therapeutics PLC on 4.

Valuation

Metric JAZZ SMMT Biotechnology median
P/E 62.55 n/m 10.26
P/S 3.12 15,883.80 9.18
P/B 3.51 17.78 2.05
Price to free cash flow 22.16 n/m 24.81
EV/EBITDA 15.24 n/m 0.65
EV/Sales 3.70 15,045.51 8.98
Earnings yield 1.60% (7.78%) (34.89%)
Free cash flow yield 4.51% (4.11%) (24.52%)

Profitability

Metric JAZZ SMMT Biotechnology median
Gross margin 89.09% 100.00% 65.16%
Operating margin 9.03% 0.00% 0.00%
Net margin 4.37% 0.00% 0.00%
Free cash flow margin 14.08% 0.00% 0.00%
Return on equity 5.05% (192.50%) (50.12%)
Return on assets 1.76% (159.09%) (45.60%)
Return on invested capital 3.86% 0.00% 0.00%

Growth

Metric JAZZ SMMT Biotechnology median
Revenue growth (TTM) 13.48% (61.03%) 6.26%
EPS growth (last fiscal year) (167.51%) (364.52%) 29.88%
Revenue growth, 5-year CAGR 12.54% (46.49%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric JAZZ SMMT Biotechnology median
Debt to equity 1.33 0.00 0.00
Current ratio 1.82 6.96 4.89
Net debt to EBITDA 10.96 0.65 1.01

Dividend

Metric JAZZ SMMT Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric JAZZ SMMT Biotechnology median
Market cap 14.59b 11.32b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack